Study of Mesenchymal Stem Cells and Their Secretome as Additional Treatment for Severe ARDS Due to Pneumonia in Adults 40 and Older

What this Trial Is About

Researchers are evaluating the effects of Umbilical Cord Mesenchymal Stem Cells UC-MSC and Secretome as additional treatments for patients with severe Acute Respiratory Distress Syndrome ARDS. This randomized, double-blind clinical trial compares three groups to assess their impact on lung injury and inflammation. The study aims to see if these therapies can reduce injury scores and improve laboratory markers related to inflammation and organ function. Participants are divided into three groups one receiving standard care plus a placebo, one receiving UC-MSC infusions plus placebo nasal drops, and one receiving UC-MSC infusions combined with Secretome nasal drops. The UC-MSC is given intravenously at a dose of 10 million cells per kg on days 2, 5, and 8, while nasal drops either Secretome or growth medium as placebo are administered on days 1, 4, and 7. This controlled experimental study compares the outcomes among these groups to evaluate treatment success. During the study, participants undergo multiple assessments including chest X-rays, hypoxemia and respiratory compliance scores, and laboratory tests such as complete blood count, D-dimer, Procalcitonin, CRP, and inflammatory factors IL-6, IL-12, and TNF-alpha. Lung injury and organ function scores are measured at several time points up to day 28. The study tracks changes in these markers to evaluate the effects of the treatments over the course of the trial, which is expected to continue until December 2026.

Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis